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Chemokine (C-C motif) ligand-2 (CCL2) is a chemoattractant and activator of macrophages and is a key determinant of the
macrophage infiltrate into tumours. We demonstrate here that CCL2 is expressed in normal human ovarian surface epithelium
(HOSE) cells and is silenced in most ovarian cancer cell lines, and silenced or downregulated in the majority of primary ovarian
adenocarcinomas. Analysis of the CCL2 locus at 17q11.2–q12 showed loss of heterozygosity (LOH) in 70% of primary tumours, and
this was significantly more common in tumours of advanced stage or grade. However, we did not detect any mutations in the CCL2
coding sequence in 94 primary ovarian adenocarcinomas. These data support the hypothesis that CCL2 may play a role in the
pathobiology of ovarian cancers, but additional studies will be required to evaluate this possibility.
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Ovarian cancer is the leading cause of death from gynaecological
neoplasias, and the sixth most common cancer among women
worldwide (Parkin et al, 1999). The lack of symptoms during the
early stages of the disease results in the majority of women
presenting with advanced tumours that do not respond well to
treatment. Consequently, the overall 5-year survival rate is only
30%. Most ovarian cancers, the adenocarcinomas, arise as a
consequence of the accumulation of genetic or epigenetic
inactivation of tumour suppressor genes and activation of
oncogenes in the ovarian surface epithelium (OSE) (reviewed in
Aunoble et al, 2000; Liu and Ganesan, 2002). Ovarian neoplasms
occur in benign, low malignant potential (LMP) and malignant
forms although the relationship between these forms is not clear,
nor are the genetic and biological events that underlie the
initiation and progression of ovarian adenocarcinomas.
Ovarian tumours may contain a significant number of infiltra-
ting host leukocytes, and in the case of ovarian cancers, these are
predominantly macrophages and T cells (Merogi et al, 1997; Negus
et al, 1997). The likely stimulus for the presence of these leukocytes
is the local production of chemokines. Chemokines are a family of
small, secreted, proinflamatory cytokines with chemotactic activity
against leukocytes (Oppenheim et al, 1991). In particular,
chemokine (C-C motif) ligand 2 (CCL2, previously known as
monocyte chemotactic protein-1, MCP-1), which is a potent
chemoattractant for macrophages (Sica et al, 1990), and also T
cells (Taub et al, 1995), has been found to be expressed in ovarian
tumours (Negus et al, 1995; Burke et al, 1996) and appears to be an
important determinant of the leukocyte infiltrate into tumours
(Zacchariae et al, 1990; Rollins, 1991; Bottazzi et al, 1992; Negus
et al, 1997; Zhang et al, 1997).
However, the role of these tumour-associated leukocytes
remains unclear (Mantovani et al, 1992; Mantovani, 1994;
O’Sullivan and Lewis, 1994). It is known that they can mount
an immune response against malignant cells and kill them
(Parmiani et al, 1990; Rollins and Sunday, 1991; Colombo
et al, 1992; Peoples et al, 1995; Goedegebuure et al, 1997) and,
indeed, the presence of intratumoural T cells in ovarian cancer
patients has been shown to be significantly associated with
increased progression-free and overall survival (Zhang et al,
2003). On the other hand, macrophages can produce factors that
help tumour growth and/or vascularisation through paracrine
loops (Malik and Balkwill, 1991; Mantovani et al, 1992). The
particular role of these cells in a given case depends on factors
such as the activation state of the macrophages and the intrinsic
properties of the tumour cell, and is known as the macrophage
balance (Mantovani, 1994).
Using cDNA array screening of normal OSE cells and ovarian
cancer cell lines, we previously identified CCL2 as a gene whose
expression is downregulated or lost in ovarian cancer cell lines
(Arnold et al, 2001a). In this report, we describe the characterisa-
tion of CCL2 expression in a larger panel of ovarian cancer cell
lines and primary tumours and mutation analysis of the CCL2 gene
in primary ovarian adenocarcinomas.
MATERIALS AND METHODS
Cell lines, OSE cultures and primary tumours
Human ovarian surface epithelial cell lines (HOSE) 17.1 and 1.1,
immortalised with a replication-defective retroviral construct
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sexpressing human papillomavirus oncogenes (Tsao et al, 1995),
were maintained in a medium composed of 1:1 M199:MCDB105
with 10% FCS. The HEY (Buick et al, 1985) and OVCAR4,
OVCAR5 and OVCAR8 (kind gift from Dr E Marshall, Auckland
Cancer Society) and OVHS-1 (kind gift of Dr N Ahmed, Royal
Women’s Hospital, Melbourne) ovarian cancer cell lines were
maintained in MEM alpha medium with 10% FCS. OAW 42
(Wilson, 1984), OAW 28þ53 (Wilson et al, 1987), PEO1 and PEO4
(Wolf et al, 1987), PEO14 (Langdon et al, 1988), JAM (Ward et al,
1987), SKOV3 (Fogh and Trempe, 1975), COLO316 (Woods
et al, 1979), CAOV3 (Wong et al, 1999), OVCAR-3 (Hamilton
et al, 1983), A2780 (established by Dr S Aaronson, National Cancer
Institute), CI80135 and 27/87 (established by T Hurst, Obstetrics
and Gynecology, Royal Brisbane Hospital) were all maintained in
RPMI 1640 with 10% FCS. OVCA420, OVCA432, OVCA433 and
DOV13 (kind gifts from Dr S Mok, Laboratory of Gynecologic
Oncology, Brigham and Women’s hospital, Boston, MA, USA)
were maintained in a mixture of 1:1 MCDB105 and M199 with
10% FCS.
Cells were harvested for RNA at about 80% confluence. The cell
lines OAW42, PEO1, PEO4, PEO14, JAM, SKOV3 and COLO316
were derived from serous tumours, and 27/87 was from an
endometrioid tumour. The histological origin of the remaining cell
lines is not available.
Uncultured HOSE cells were obtained by scraping stromal cells
away from epithelial sheets. Their distinctive cellular morphology
was used to confirm that the cells were epithelial. RNA was
extracted directly from these peeled epithelial cells without
culturing.
Ovarian adenocarcinomas were obtained from 97 patients
undergoing surgery. There were 68 serous tumours, 13 endome-
trioid tumours, nine mucinous tumours, five clear-cell tumours
and two tumours of mixed histology. The series included one
benign and 10 LMP tumours as well as 86 malignant tumours. All
patients were staged at laparotomy, in accordance with the
recommendations of the International Federation of Gynaecology
and Obstetrics (FIGO). Of the LMP tumours, five were FIGO stage
1 and four were stage 3 (one was of unknown stage) and of the
malignant tumours, seven were FIGO stage 1, five stage 2, 66 stage
3 and eight stage 4. Constitutional DNA was available in all cases
from peripheral blood.
Isolation of DNA and RNA
Tumour tissue was dissected free from necrotic and connective
tissue, and mechanically dispersed prior to collagenase treatment
(0.1mgml
 1 in Hanks balanced salt solution). Erythrocytes and
necrotic cells were removed with ficoll-paque, and genomic DNA
was extracted by the salting-out method as described elsewhere
(Miller et al, 1988). Total RNA was extracted from fresh primary
tumours and subconfluent cultured cell lines using Tri-reagent
(Sigma, Castle Hill, NSW), following the manufacturers’ instruc-
tions. PolyAþ RNA was prepared from total RNA using
Dynabeads (Dynal, Carlton South, Vic), according to the
recommended protocol.
Northern blot analysis
RNA was denatured and electrophoresed on a formaldehyde–
agarose gel and transferred onto a nylon membrane by capillary
blotting overnight according to standard protocols (Sambrook and
Russell, 2001). The RNA was then fixed to the membrane by UV
irradiation. Probes were prepared from RT–PCR products by
random priming and hybridisation was carried out for 2h in
ExpressHyb solution (Clontech, Palo Alto, CA, USA) at 651C and
then the membrane was subjected to standard washing procedures
and autoradiography.
Semiquantitative RT–PCR
cDNA synthesis was carried out with the Superscript II reverse
transcriptase on 1mg of total RNA primed with random hexamers.
RT–PCR was performed with primers for both CCL2 and b-actin
in a multiplex reaction in a total volume of 20ml incorporating
33P-
labelled dATP using standard PCR cycling conditions with
annealing at 601C. The reaction was stopped and 5ml of product
removed at cycles 24, 28, 32 and 36 to ensure linear amplification
and the products were run on a denaturing acrylamide gel prior to
autoradiography. The primer sequences for both CCL2
(CTAAGCTTCCAGCATGAAAGTCTCTGG and GTGAGTGTTCAA
GTCTTCG) and b-actin (CGTGACATTAAGGAGAAGCTGTGC and
CTCAGGAGGAGCAATGATCTTGAT) spanned at least one intron
to ensure quantitation was assessed only on amplified cDNA.
mRNA in situ hybridisation (ISH)
The CCL2 full-length cDNA was subcloned into pGEM-T vector
(Promega, Annandale, NSW). Digoxigenin-labelled riboprobes for
sense and antisense orientations were produced by in vitro
transcription with SP6 and T7 RNA polymerases (Roche,
Mannheim, Germany) as previously described (Ramm et al,
1998) and then subjected to alkaline hydrolysis. Sections were
deparaffinised with xylene, rehydrated in an alcohol gradient and
subjected to hydrochloric acid (0.2moll
 1), as previously de-
scribed (Rex and Scotting, 1994). Sections were permeabilised with
20mgml
 1 proteinase K for 15min at 371C and fixed in 4%
paraformaldehyde for 20min at room temperature. Prehybridisa-
tion (4  SSC/50% (vv
 1) formamide) was performed at 421C for
4h followed by hybridisation for 18h at 421C with digoxigenin-
labelled riboprobe at a concentration of 1mgml
 1 in a solution of
40% (vv
 1) formamide, 10% (wv
 1) dextran sulphate, 1 
Denhardt’s solution, 4  SSC, 10mM DTT and 1mgml
 1 yeast
tRNA.
Sections were washed to remove unbound probe and then
incubated with alkaline phosphatase-conjugated antidigoxigenin
polyclonal sera (1:100) (Roche, Mannheim, Germany) at room
temperature for 2h. Unbound antibody was removed by washing,
followed by visualisation with nitroblue tetrazolium chloride/5-
bromo-4-chloro-3-indolyl phosphate (Roche, Mannheim, Germany)
in the dark at room temperature for 18h. Unbound complex
was removed by washing and sections were counterstained with
eosin. Sections were visualised with a Nikon Eclipse E800
microscope and photographed with a Nikon DXM1200F digital
camera.
Loss of heterozygosity (LOH) analyses
Loss of heterozygosity was assessed at 17q11.2–q12 with the
D17S1293 and D17S933 microsatellite markers, which are located
0.02Mb proximal and 0.61Mb distal to CCL2 at 32.73Mb
(www.ncbi.nlm.nih.gov/). PCR amplification was carried out for
35 cycles in the presence of
33P-labelled dATP and PCR products
were analysed on a denaturing polyacrylamide gel. Loss of
heterozygosity was scored conservatively as a clear reduction in
the intensity of one allele (470%) by two independent observers,
one of whom was blind with respect to the sample identity.
Single-strand conformation polymorphism analysis
Primers were designed to intronic regions to amplify each of the
three coding exons of the human CCL2 gene. A total of 94 primary
ovarian tumours obtained prior to chemotherapy were screened
and constitutional DNA from blood was available for all. DNA
samples were amplified in the presence of
33P-labelled dATP using
standard PCR cycling conditions with annealing at 601C,
denatured at 951C for 5min and then electrophoresed on 0.5 
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sMDE (FMC Biotech, Rockland, Maine) gel overnight at room
temperature.
The primers used for SSCP and product sizes were: exon 1
CAATAAGAGGCAGAGACAGCAGCCAG and GTTAAAGCAAGAC
TGTGGGTACCACG (273bp); exon 2 GCTCTTTCTCTTCTCCTGC
CTGC and GAGGCTTGTCCCTTGCTCCACAAGG (300bp); exon 3
CCTCCTAGTCTCCATGGCAGCTCGC and ACAGGGTGTCTGGGG
AAAGCTAGG (253bp). PCR products amplified from these
primers span all coding exons of the CCL2 gene and include
sequences 72bp upstream of the start codon, 44bp downstream of
the stop codon and at least 40bp of flanking intronic sequences
exclusive of the primers.
5-aza-20-deoxycytidine treatment of ovarian
adenocarcinoma cell lines
Cell lines were plated at 20–30% confluence and treated 24h
later (day 0) with 0, 0.5 or 2.0mM 5-aza-20-deoxycytidine. Fresh
media containing the same concentration of 5-aza-20-deoxycyti-
dine was added on day 2 and cells were harvested for RNA
extraction on day 5.
RESULTS
CCL2 expression analysis in ovarian adenocarcinoma
cell lines
We previously conducted a screen for genes aberrantly expressed
in three ovarian adenocarcinoma cell lines compared to an
immortalised HOSE using a human cDNA array containing 588
known genes (Arnold et al, 2001a). This showed that expression of
CCL2 is greatly reduced in ovarian cancer cell lines. This finding
was confirmed using semiquantitative RT–PCR analysis which
showed that CCL2 was expressed in both of the HOSE cell lines
tested, while three out of four ovarian cancer cell lines did not
express and one out of four had reduced levels of expression
(Arnold et al, 2001a).
To further extend these results, semiquantitative RT–PCR was
repeated to include peeled (uncultured) normal OSE cells as well as
the HOSE17.1 cell line and a broader panel of ovarian cancer cell
lines. Expression of CCL2 was detected at similar levels in the
HOSE17.1 cell line, the uncultured normal OSE cells, and the
PEO14 and 27/87 ovarian cancer cell lines (Figure 1A, B). No CCL2
expression was detected in the remaining seven ovarian adeno-
carcinoma cell lines, even after 36 rounds of PCR amplification
(Figure 1C).
The expression of CCL2 mRNA was next examined in a larger
panel of HOSE and ovarian cancer cell lines by Northern blot
analysis (Figure 2). Strong expression was detected in the
HOSE17.1 and HOSE1.1 cell lines, while much weaker expression
was found in the PEO14 and 27/87 cell lines. No expression was
detected in the remaining 16 ovarian adenocarcinoma cell lines.
CCL2 expression analysis in primary ovarian
adenocarcinomas
Having demonstrated that CCL2 is strongly expressed in cultured
and uncultured HOSE cells, and that expression is lost or reduced
in the vast majority of ovarian cancer cell lines, we next
investigated its expression in primary ovarian tumours. Northern
blot analysis of the HOSE17.1 cell line and 13 primary
adenocarcinomas revealed greatly reduced levels of expression in
two primary tumours (35 out of 90 and 33 out of 91) compared to
the HOSE17.1 cells, while no expression was detected in the
remaining 11 primary tumours (Figure 3).
To further investigate the extent and localisation of CCL2
expression in primary ovarian tumours, we used mRNA ISH to
analyse two normal ovaries and 13 primary adenocarcinomas. This
series included nine adenocarcinomas that we had previously
investigated by Northern blot. A pathologist (MC) scored the
percent of expressing cells into categories. No CCL2 expression
was detected in the stroma of any of the tumours. Four tumours
expressed CCL2 in 0–5% of epithelial cells, six tumours expressed
CCL2 in 6–25% of epithelial cells, while only three tumours
expressed CCL2 in greater than 25% of the epithelial cells. In the
normal ovaries, CCL2 expression was detected in 60–80% of the
surface epithelial cells and also epithelial cells lining invaginations
and inclusion cysts. Representative photomicrographs of CCL2
staining in a normal ovary and three tumours are shown in
Figure 4.
There were nine tumours, which were analysed by both ISH and
Northern blot. Of the seven tumours in which expression was not
detected by Northern blot, six had less than 25% epithelial cells
expressing, while one (61 out of 93) had 26–50%, and of the two
which did show expression on the Northern blot, one tumour was
scored as having 50–75% expression while the other was scored as
6–25%. The lack of correlation between these two methods in tumour
61 out of 93 is probably due to tumour heterogeneity, since the sections
used for ISH were not adjacent to the tissue used to isolate RNA.
5-azacytidine treatment of cell lines
To test whether the silencing of CCL2 expression in the ovarian
cancer cell lines is related to hyper-methylation of CpG dinucleo-
tides, we treated cell lines with 0, 0.5 or 2.0mM of the methyl-
transferase inhibitor 5-azacytidine. RNA was extracted from the
cultures after 5 days and the level of expression of CCL2 was
examined by semiquantitative RT–PCR (Figure 5). Consistent with
previous results, the untreated controls showed no CCL2 expres-
sion in the OAW42, JAM, HEY, SKOV3, COLO316 or CAOV3 cell
lines, while strong expression was observed in the PEO14 cells.
There was a slight induction of CCL2 expression in the OAW42
cell line treated with 0.5mM 5-azacytidine, but no induction of
expression in any of the other six cell lines (Figure 5A). Previous
analysis of the same RNA samples for ICAM-1 expression (Arnold
et al, 2001b) showed induction of ICAM-1 in cell lines treated with
5-azacytidine, demonstrating that the 5-azacytidine treatment was
successful (Figure 5B, C).
Loss of heterozygosity analysis at 17q11.2–q12
Loss of heterozygosity analysis was carried out on 41 ovarian
adenocarcinomas with the D17S1293 and D17S933 microsatellite
HOSE17.1
PEO1
OAW42
JAM
HEY
SKOV3
COLO316
OVCAR3
27/87
PEO14
PEELED OSE
CCL2
28 cycles
-actin
28 cycles
CCL2
36 cycles
A
B
C
Figure 1 Analysis of CCL2 expression in immortalised HOSE cells,
peeled (uncultured) OSE cells and ovarian adenocarcinoma cell lines by
RT–PCR. Multiplex PCR was carried out for CCL2 and b-actin on cDNA,
run on a polyacrylamide gel, and exposed to film. (A) PCR products for
b-actin after 28 cycles of amplification. (B) PCR products for CCL2 after 28
cycles of amplification. (C) PCR products for CCL2 after 36 cycles of
amplification.
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smarkers, which are located 0.02Mb proximal and 0.61Mb distal to
CCL2 at 32.73Mb (www.ncbi.nlm.nih.gov/). Loss of heterozygosity
was detected in 19 out of 27 (70%) informative cases for D17S1293
and 19 out of 26 (73%) informative cases for D17S933. Overall,
LOH was detected in at least one marker in 22 out of 32 (69%) of
informative cases. The LOH was significantly more common in
Stage 3–4 tumours than Stage 1–2 tumours (P¼0.03, Fisher’s
exact test), and tended to occur in tumours of advanced grade
(P¼0.058, Mantel–Haenszel w
2 test for trend). Of the informative
tumours that did not express CCL2 by Northern blot, six had LOH
and one had no loss, while one tumour that did express CCL2 also
had LOH. Similarly, of the informative tumours that had 0–25%
cells positive for CCL2 by ISH, four had LOH and two had no loss,
while there were two tumours with greater than 26% of cells
positive that both had LOH.
Mutation analysis of the CCL2 gene
Single-strand conformation polymorphism (SSCP) analysis was
carried out on all three exons of the CCL2 gene, including
sequences 72bp upstream of the start codon and 44bp down-
stream of the stop codon and at least 40bp of flanking intronic
sequences surrounding each exon. There were no aberrant bands
detected in the PCR of any exon of CCL2 in the panel of 94 primary
ovarian adenocarcinomas tested.
DISCUSSION
We first detected CCL2 as a gene whose expression is down-
regulated in ovarian adenocarcinoma cell lines relative to OSE cells
by cDNA array (Arnold et al, 2001a). Further analysis of CCL2
CCL2
0.7 kb
HOSE17.1
HOSE1.1
PEO1
OAW42
JAM
HEY
SKOV3
COLO316
OVCAR3
27/87
PEO14
A2780
OVHS-1
DOV13
OVCAR4
OVCAR5
OVCAR8
OVCA420
OVCA432
OVCA433
GAPDH
1.3 kb
A
B
Figure 2 Analysis of CCL2 expression in HOSE and ovarian adenocarcinoma cell lines by Northern blotting. Each lane represents 2mg of polyAþ RNA.
(A) Hybridisation with the CCL2 probe. (B) Hybridisation with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe.
CCL2
0.7 kb
52/92
HOSE17.1
8/93
13/93
35/90
2/92
62/91
69/89
4/92
33/91
99/93
65/93
61/93
36/94
GAPDH
1.3 kb
A
B
Figure 3 Analysis of CCL2 expression in ovarian primary adenocarcinomas by Northern blotting. Lane 1, HOSE17.1 cell line; lanes 2–9, ovarian serous
adenocarcinomas; lanes 10–13 ovarian endometrioid adenocarcinomas; lane 14 mucinous ovarian adenocarcinoma. Each lane represents 5mg of total RNA.
(A) Hybridisation with the CCL2 probe. (B) Hybridisation with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe.
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sexpression presented here confirms that it is strongly expressed
in peeled (uncultured) normal HOSE cells and immortalised cell
lines derived from OSE cells. Expression is silenced in most
ovarian cancer cell lines and silenced or downregulated in the
majority of ovarian primary adenocarcinomas. This suggests that a
selective advantage may result from downregulation of CCL2
expression, consistent with a role of CCL2 in the pathobiology of
ovarian cancer.
A previous study of CCL2 expression in seven ovarian cancer
cell lines by RT–PCR and ELISA, found the highest levels in
PEO14 and HL60, with lower levels in OVCAR3, PEO1 and PEO4
and barely detectable expression in SKOV3 and PEA2 cells (Negus
et al, 1995). This is consistent with our results in which we also
found high levels of CCL2 mRNA in PEO14 and no expression in
most other cell lines. In primary tumours, mRNA ISH showed
expression of CCL2 in an average of 1.4% of cells in 23 out of 26
primary ovarian tumours, and ELISA detected CCL2 protein in
ascites from ovarian cancer patients with a mean level of
4.28ngml
 1 (Negus et al, 1995). This is also consistent with our
Northern blot results, although we detected higher levels of
expression than Negus et al by ISH. The same study did not detect
CCL2 mRNA in the normal ovarian mesothelium (OSE), which was
examined in only one case. In contrast, we have demonstrated
strong expression in both cultured immortalised and uncultured
OSE cells by RT–PCR, Northern blotting and ISH. This is an
important new finding and demonstrates that CCL2 expression is
silenced or downregulated in the majority of ovarian cell lines and
primary tumours.
Expression of CCL2 has also been found to be decreased in
prostate adenocarcinoma compared to benign prostate hyperplasia
(Mazzucchelli et al, 1996) and cervical carcinomas compared to
normal or hyperplastic squamous epithelium (Riethdorf et al,
1998; Kleine-Lowinski et al, 1999). In contrast, CCL2 expression
has been found to be increased in malignant glioma (Kuratsu et al,
1993; Takeshima et al, 1994), primary and metastatic melanoma
(Graves et al, 1992) and glioblastomas and astrocytomas (Desbaillets
et al, 1994) compared to corresponding normal tissues. CCL2
expression has also been found to be increased in paclitaxel
resistant cell lines and in the serum of ovarian cancer patients
following paclitaxel treatment (Duan et al, 1999; Penson et al,
2000). However, rather than being associated with paclitaxel
resistance, it is postulated that the increased CCL2 expression may
simply reflect stress in the host (Penson et al, 2000).
To investigate the mechanism of downregulation of expression
of CCL2, we treated a panel of ovarian cancer cell lines with the
methyltransferase inhibitor 5-azacytidine. This resulted in a small
increase in expression levels in only the OAW42 cell line, while
there was no induction of expression in the other six. This suggests
that hypermethylation of CpG islands near the CCL2 gene is not
the major cause of the silencing of expression. Indeed, a search of
AB
CD
EF
Figure 4 In situ hybridisation of CCL2 in ovarian tumours and normal ovaries. Normal ovary hybridised with (A) antisense CCL2 probe ( 40) and (B)
sense control probe ( 40) showing staining in the majority of surface epithelial cells. Ovarian adenocarcinomas hybridised with antisense CCL2 probe
(C, D, E) or sense control probe (F). Tumours 97/93 (C,  40) and 99/93 (D,  40) show very little staining for CCL2. Ovarian adenocarcinoma 52/92
hybridised with (E) antisense CCL2 probe ( 40) and (F) sense control probe ( 20). The majority of 52/92 tumour cells in this field show CCL2
expression.
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sthe CCL2 genomic region from 7kb upstream of the start codon to
2.5kb downstream of the stop codon (GenBank Accession Number
Y18933) using Cpgplot (www.angis.org.au) did not detect any CpG
islands, which further supports our findings.
We next investigated whether genetic changes may be respon-
sible for the downregulation of CCL2 expression. There was no
evidence of any mutations in the CCL2 gene in 94 primary ovarian
adenocarcinomas, demonstrating that CCL2 is not inactivated by
somatic mutations, nor is downregulation of its expression the
result of mutation in the coding or adjacent flanking sequences.
There are five single-nucleotide polymorphisms reported within
the CCL2 locus (http://www.ncbi.nih.gov/SNP/); however, only two
of these were within the region screened for mutations and each of
these had minor allele frequencies of less than 0.5% so it is not
surprising that these were not detected within the 94 ovarian
cancer samples we screened.
An overall LOH frequency of 69% was detected at the CCL2 locus
at 17q11.2–q12, but there was no association with loss of CCL2
expression. Loss of heterozygosity on chromosome 17 frequently
involves the whole chromosome (Shelling et al, 1995), but minimal
regions of loss have been detected at 17p13, 17q12.2, 17q21 and
17q25.1–qter (Liu and Ganesan, 2002). Our finding of high rates of
LOH at 17q11.2–q12 places this region among the most frequently
deleted regions in ovarian cancer (Shelling et al, 1995; Liu and
Ganesan, 2002). The fact that this LOH is significantly more common
in late stage than early stage tumours, indicates that it is associated
with progression rather than initiation. Further analysis of 17q is
required to refine the minimal region of deletion at 17q11.2–q12 and
to determine whether CCL2 is the target of this loss.
Transfection with human CCL2 has been reported to suppress
the in vivo growth and tumorigenicity of CHO cells (Rollins and
Sunday, 1991) and melanoma cells (Bottazzi et al, 1992), and the
fusion of tumorigenic HeLa cells, which do not express CCL2, with
normal fibroblasts, resulted in CCL2 expressing somatic hybrids
unable to form tumours in nude mice (Rosl et al, 1994). In
contrast, no effect on tumour growth was found for human or
murine CCL2 transfected into colon adenocarcinoma cells (Hirose
et al, 1995). We transfected the HEY and OVCAR8 ovarian cancer
cell lines with CCL2 cloned into pcDNA3.1, but were unable to
develop stable clones with comparable levels of expression to the
HOSE cells, and so were unable or to interpret the consequences of
in vitro or in vivo assays (data not shown).
The consequences of the introduction of CCL2 into biologically
early, nontumorigenic melanoma cells were found to depend on the
level of CCL2 secretion (Nesbit et al, 2001). Low level secretion was
found to stimulate tumour growth through angiogenesis mediated by
monocyte activation, whereas high levels of CCL2 attracted large
numbers of monocytes/macrophages and rapid tumour destruction
(Nesbit et al, 2001). Thus, it appears that the levels of CCL2 may
determine the biological effect. The reduced levels of CCL2 found in
ovarian cancers may be promoting tumour growth through various
growth factors produced by monocytes attracted to the tumour, in
addition to evading the destructive response of the host macrophages
and T cells. This concept requires more investigation in ovarian
cancer and other neoplasias.
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Figure 5 Analysis of CCL2 expression in ovarian cancer cell lines following treatment with 5-azacytidine. Cell lines were treated with 0 (X), 0.5 (Y) or 2.0
(Z) mM 5-azacytidine and RNA harvested 5 days later. (A) Multiplex PCR carried out with primers for b-actin and CCL2 for 28 cycles. (B) Multiplex PCR
carried out with primers for b-actin and ICAM-1 as previously described (Arnold et al, 2001b). (C) Quantitation of intensity of bands for ICAM-1 normalised
to b-actin.
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